Marshall Wace LLP Has $27.83 Million Position in Pfizer Inc. (NYSE:PFE)

Marshall Wace LLP trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.5% in the first quarter, HoldingsChannel reports. The firm owned 655,261 shares of the biopharmaceutical company’s stock after selling 45,570 shares during the period. Marshall Wace LLP’s holdings in Pfizer were worth $27,829,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Belpointe Asset Management LLC lifted its stake in Pfizer by 4.5% during the first quarter. Belpointe Asset Management LLC now owns 96,698 shares of the biopharmaceutical company’s stock worth $4,107,000 after purchasing an additional 4,154 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC bought a new stake in Pfizer during the first quarter worth $386,000. Brick & Kyle Associates lifted its stake in Pfizer by 9.1% during the first quarter. Brick & Kyle Associates now owns 9,747 shares of the biopharmaceutical company’s stock worth $414,000 after purchasing an additional 814 shares during the last quarter. Putnam FL Investment Management Co. lifted its stake in shares of Pfizer by 25.1% in the 4th quarter. Putnam FL Investment Management Co. now owns 162,325 shares of the biopharmaceutical company’s stock valued at $7,086,000 after acquiring an additional 32,529 shares during the last quarter. Finally, B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund bought a new position in shares of Pfizer in the 4th quarter valued at $1,367,000. 71.88% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $42.83, for a total value of $642,450.00. Following the transaction, the insider now owns 124,994 shares of the company’s stock, valued at approximately $5,353,493.02. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Pfizer Inc purchased 50,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

A number of research analysts have recently commented on PFE shares. Zacks Investment Research cut Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, March 28th. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a research note on Tuesday, February 19th. Citigroup reiterated a “neutral” rating and issued a $41.00 price target on shares of Pfizer in a research note on Wednesday, February 20th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $46.00 price target on shares of Pfizer in a research note on Friday, April 19th. Finally, Bank of America increased their price target on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Thirteen research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus price target of $46.00.

NYSE PFE traded up $0.26 on Friday, reaching $42.76. The company had a trading volume of 12,521,684 shares, compared to its average volume of 20,710,772. The company has a market capitalization of $237.74 billion, a price-to-earnings ratio of 14.25, a PEG ratio of 2.47 and a beta of 0.65. Pfizer Inc. has a fifty-two week low of $35.73 and a fifty-two week high of $46.47. The company has a quick ratio of 1.27, a current ratio of 1.54 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.10. The business had revenue of $13.12 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. Pfizer’s quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.77 earnings per share. Research analysts expect that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 7th. Shareholders of record on Friday, May 10th were issued a dividend of $0.36 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a yield of 3.37%. Pfizer’s payout ratio is currently 48.00%.

TRADEMARK VIOLATION NOTICE: This report was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Trade Deficit

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit